Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • smalan
    Junior Member
    • Feb 2012
    • 8

    Cut-off values for fold change in RNA seq

    Hi. I am new at RNA seq. Our bioinformaticist has asked me to provide them with cut-off values for fold change and p-values to use in our differential expression analysis. I have seen some variation in different papers, ranging from 1.5 to those using between 1.8 and 2 for fold change and then p<0.05 and p<0.01. What is the general consensus regarding these values?
    Thanks.
  • mbblack
    Senior Member
    • Aug 2009
    • 245

    #2
    Any cutoff is arbitrary, so it really is a matter of what you think is an acceptable level of control for false positives and a reasonable level for biologically relevant or interesting changes.

    The group I work with generally use a fold change cutoff of +/- 1.5 and an FDR of < 0.05. Going to a fold change of 2 tends to cause us to loose too many interesting and relevant genes, and pushing the FDR to less seems too stringent and so again, we risk missing biologically interesting and relevant genes. But, it really is arbitrary what you pick.

    Personally, I'd ask that your analyst return you a list of all p-values, FDR values and fold change for all genes and let you filter them to see what cutoffs give you workable gene lists without being overly stringent or overly lax. There is no hard and fast rule here - the trick is to get biologically valuable gene lists without risking too many false positives or throwing out important genes with too a stringent cutoff. It is something you need to look at in the context of the whole results and the context of your specific biological system and experimental question(s), not just randomly pick a value out of thin air and rigidly apply it.

    I always save the full tables from my analyses (with R/BioConductor tools it is simple to output a tab delimited table of results for all genes) and then filter those afterwards to see what I get back out with different cutoffs to decide what my final choice will be to create gene lists to go forward with.
    Last edited by mbblack; 07-12-2012, 10:18 AM.
    Michael Black, Ph.D.
    ScitoVation LLC. RTP, N.C.

    Comment

    Latest Articles

    Collapse

    • SEQadmin2
      Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
      by SEQadmin2


      Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

      The systematic characterization of the human proteome has
      ...
      Yesterday, 11:48 AM
    • SEQadmin2
      Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
      by SEQadmin2



      Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
      ...
      07-09-2026, 11:10 AM
    • SEQadmin2
      Cancer Drug Resistance: The Lingering Barrier to Rising Survival
      by SEQadmin2



      Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

      There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
      07-08-2026, 05:17 AM

    ad_right_rmr

    Collapse

    News

    Collapse

    Topics Statistics Last Post
    Started by SEQadmin2, Yesterday, 11:10 AM
    0 responses
    9 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-13-2026, 10:26 AM
    0 responses
    30 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-09-2026, 10:04 AM
    0 responses
    40 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-08-2026, 10:08 AM
    0 responses
    25 views
    0 reactions
    Last Post SEQadmin2  
    Working...